Cargando…

Evaluating the Impact of CYP3A5 Genotype on Post-Transplant Healthcare Resource Utilization in Pediatric Renal and Heart Transplant Recipients Receiving Tacrolimus

PURPOSE: CYP3A5 genotype is a significant contributor to inter-individual tacrolimus exposure and may impact the time required to achieve therapeutic concentrations and number of tacrolimus dose adjustments in transplant patients. Increased modifications to tacrolimus therapy may indicate a higher b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pasternak, Amy L, Marshall, Vincent D, Gersch, Christina L, Rae, James M, Englesbe, Michael, Park, Jeong M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967030/ https://www.ncbi.nlm.nih.gov/pubmed/33746516 http://dx.doi.org/10.2147/PGPM.S285444

Ejemplares similares

Transplant Recipients Using Tacrolimus Had Higher Utilization of Healthcare Services Than Those Receiving Cyclosporine in Taiwan
por: Lin, Yi-Chang, et al.
Publicado: (2019)

CYP3A5 and ABCB1 genotype influence tacrolimus and sirolimus pharmacokinetics in renal transplant recipients
por: Li, Yi, et al.
Publicado: (2015)

Differences in CYP3A genotypes of a liver transplant recipient and the donor liver graft and adjustment of tacrolimus dose
por: Berger, Florine A., et al.
Publicado: (2019)

CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment
por: Chen, Lucy, et al.
Publicado: (2018)

Genotype-guided tacrolimus dosing in African American kidney transplant recipients
por: Sanghavi, K., et al.
Publicado: (2015)

Efficacy and safety of tacrolimus in de novo pediatric transplant recipients randomized to receive immediate‐ or prolonged‐release tacrolimus
por: Vondrak, Karel, et al.
Publicado: (2019)

Prediction of Tacrolimus Exposure by CYP3A5 Genotype and Exposure of Co-Administered Everolimus in Japanese Renal Transplant Recipients
por: Kagaya, Hideaki, et al.
Publicado: (2018)

Limited sampling strategies for estimation of tacrolimus exposure in kidney transplant recipients receiving extended‐release tacrolimus preparation
por: El‐Nahhas, Toqa, et al.
Publicado: (2021)

The Clinical Impact of the C(0)/D Ratio and the CYP3A5 Genotype on Outcome in Tacrolimus Treated Kidney Transplant Recipients
por: van Gelder, Teun, et al.
Publicado: (2020)

The CYP3A5 genotypes of both liver transplant recipients and donors influence the time‐dependent recovery of tacrolimus clearance during the early stage following transplantation
por: Huang, Li, et al.
Publicado: (2021)

CYP3A-status is associated with blood concentration and dose-requirement of tacrolimus in heart transplant recipients
por: Déri, Máté, et al.
Publicado: (2021)

Tacrolimus trough levels in kidney transplant recipients
por: Hwang, Young Hui, et al.
Publicado: (2021)

Tacrolimus dose requirement based on the CYP3A5 genotype in renal transplant patients
por: Qu, Lihui, et al.
Publicado: (2017)

Effects of CYP3A5 Genotypes on Thrombocytopenia in Liver Transplantation Patients Treated with Tacrolimus
por: Guo, Zhe, et al.
Publicado: (2023)

Early impact of donor CYP3A5 genotype and Graft-to-Recipient Weight Ratio on tacrolimus pharmacokinetics in pediatric liver transplant patients
por: Pinon, Michele, et al.
Publicado: (2021)

Commentary: The Clinical Impact of the C(0)/D Ratio and the CYP3A5 Genotype on Outcome in Tacrolimus Treated Kidney Transplant Recipients
por: Thölking, Gerold, et al.
Publicado: (2021)

Massive pleural effusion in a renal transplant recipient on tacrolimus
por: Nayagam, L. S., et al.
Publicado: (2014)

The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients
por: Lunde, Ingrid, et al.
Publicado: (2014)

Personalized Tacrolimus Dose Requirement by CYP3A5 but Not ABCB1 or ACE Genotyping in Both Recipient and Donor after Pediatric Liver Transplantation
por: Chen, Yi-kuan, et al.
Publicado: (2014)

Correction: Tacrolimus dose requirement based on the CYP3A5 genotype in renal transplant patients
por: Qu, Lihui, et al.
Publicado: (2020)

Clinical Pharmacokinetics of Tacrolimus in Iranian Liver Transplant Recipients
por: Nasiri-Toosi, Zahra, et al.
Publicado: (2014)

Gout Due to Tacrolimus in a Liver Transplant Recipient
por: Afridi, Summia Matin, et al.
Publicado: (2019)

Model based development of tacrolimus dosing algorithm considering CYP3A5 genotypes and mycophenolate mofetil drug interaction in stable kidney transplant recipients
por: Kim, Jae Hyun, et al.
Publicado: (2019)

Investigation of clinical interaction between omeprazole and tacrolimus in CYP3A5 non-expressors, renal transplant recipients
por: Katsakiori, Paraskevi F, et al.
Publicado: (2010)

Epidermal Cysts in a Tacrolimus Treated Renal Transplant Recipient
por: Ahn, In Su, et al.
Publicado: (2011)

Systematic conversion to generic tacrolimus in stable kidney transplant recipients
por: Rosenborg, Staffan, et al.
Publicado: (2014)

Pharmacokinetics of tacrolimus according to body composition in recipients of kidney transplants
por: Han, Seung Seok, et al.
Publicado: (2012)

Tacrolimus Levels Are Not Associated with Risk of Malignancy in Lung Transplant Recipients
por: Fox, Benjamin Daniel, et al.
Publicado: (2017)

Pharmacokinetics of apixaban and tacrolimus or cyclosporine in kidney and lung transplant recipients
por: Mansell, Holly, et al.
Publicado: (2022)

Body composition is associated with tacrolimus pharmacokinetics in kidney transplant recipients
por: Francke, M. I., et al.
Publicado: (2022)

Tacrolimus Formulation, Exposure Variability, and Outcomes in Kidney Transplant Recipients
por: Lai, Elaine F., et al.
Publicado: (2022)

Composite CYP3A (CYP3A4 and CYP3A5) phenotypes and influences on tacrolimus dose adjusted concentration in adult heart transplant recipients
por: Hernandez, Savine, et al.
Publicado: (2023)

Efficacy and Outcomes of CYP3A5 Genotype-Based Tacrolimus Dosing Compared to Conventional Body Weight-based Dosing in Living Donor Kidney Transplant Recipients
por: Raj, T. Yashwanth, et al.
Publicado: (2022)

A Randomized Pharmacokinetic Study of Generic Tacrolimus Versus Reference Tacrolimus in Kidney Transplant Recipients
por: Alloway, R R, et al.
Publicado: (2012)

Donor CYP3A5 Gene Polymorphism Alone Cannot Predict Tacrolimus Intrarenal Concentration in Renal Transplant Recipients
por: Zhang, Mengyu, et al.
Publicado: (2020)

Impact of Tacrolimus Daily Dose Limitation in Renal Transplant Recipients Expressing CYP3A5: A Retrospective Study
por: Lenain, Rémi, et al.
Publicado: (2021)

Renal Function in De Novo Liver Transplant Recipients Receiving Different Prolonged‐Release Tacrolimus Regimens—The DIAMOND Study
por: TruneČka, P., et al.
Publicado: (2015)

Tacrolimus Pharmacokinetic and Pharmacogenomic Differences between Adults and Pediatric Solid Organ Transplant Recipients
por: Marfo, Kwaku, et al.
Publicado: (2010)

Real-World Study of Once-Daily, Extended-Release Tacrolimus Versus Twice-Daily, Immediate-Release Tacrolimus in Kidney Transplantation: Clinical Outcomes and Healthcare Resource Utilization
por: Ho, Bing, et al.
Publicado: (2019)

Genetic Polymorphisms Affecting Tacrolimus Metabolism and the Relationship to Post-Transplant Outcomes in Kidney Transplant Recipients
por: Cheng, Fang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nd1qivml4jjctjs149do4p0eeu